A murine preclinical syngeneic transplantation model for breast cancer precision medicine

Lorenzo Federico, Zechen Chong, Dong Zhang, Daniel J. McGrail, Wei Zhao, Kang Jin Jeong, Christopher P. Vellano, Zhenlin Ju, Mihai Gagea, Shuying Liu, Shreya Mitra, Jennifer B. Dennison, Philip L. Lorenzi, Robert Cardnell, Lixia Diao, Jing Wang, Yiling Lu, Lauren A. Byers, Charles M. Perou, Shiaw Yih LinGordon Mills

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We previously demonstrated that altered activity of lysophosphatidic acid in murine mammary glands promotes tumorigenesis. We have now established and characterized a heterogeneous collection of mouse-derived syngeneic transplants (MDSTs) as preclinical platforms for the assessment of personalized pharmacological therapies. Detailed molecular and phenotypic analyses revealed that MDSTs are the most heterogeneous group of genetically engineered mouse models (GEMMs) of breast cancer yet observed. Response of MDSTs to trametinib, a mitogen-activated protein kinase (MAPK) kinase inhibitor, correlated with RAS/MAPK signaling activity, as expected from studies in xenografts and clinical trials providing validation of the utility of the model. Sensitivity of MDSTs to talazoparib, a poly(adenosine 5′-diphosphate–ribose) polymerase (PARP) inhibitor, was predicted by PARP1 protein levels and by a new PARP sensitivity predictor (PSP) score developed from integrated analysis of drug sensitivity data of human cell lines. PSP score–based classification of The Cancer Genome Atlas breast cancer suggested that a subset of patients with limited therapeutic options would be expected to benefit from PARP-targeted drugs. These results indicate that MDSTs are useful models for studies of targeted therapies, and propose novel potential biomarkers for identification of breast cancer patients likely to benefit from personalized pharmacological treatments.

Original languageEnglish (US)
Article numbere1600957
JournalScience advances
Volume3
Issue number4
DOIs
StatePublished - Apr 1 2017
Externally publishedYes

Fingerprint

Isogeneic Transplantation
Precision Medicine
Breast Neoplasms
Transplants
Adenosine
Pharmacology
Atlases
Mitogen-Activated Protein Kinase Kinases
Therapeutics
Human Mammary Glands
Mitogen-Activated Protein Kinases
Heterografts
Pharmaceutical Preparations
Carcinogenesis
Biomarkers
Clinical Trials
Genome
Cell Line

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A murine preclinical syngeneic transplantation model for breast cancer precision medicine. / Federico, Lorenzo; Chong, Zechen; Zhang, Dong; McGrail, Daniel J.; Zhao, Wei; Jeong, Kang Jin; Vellano, Christopher P.; Ju, Zhenlin; Gagea, Mihai; Liu, Shuying; Mitra, Shreya; Dennison, Jennifer B.; Lorenzi, Philip L.; Cardnell, Robert; Diao, Lixia; Wang, Jing; Lu, Yiling; Byers, Lauren A.; Perou, Charles M.; Lin, Shiaw Yih; Mills, Gordon.

In: Science advances, Vol. 3, No. 4, e1600957, 01.04.2017.

Research output: Contribution to journalArticle

Federico, L, Chong, Z, Zhang, D, McGrail, DJ, Zhao, W, Jeong, KJ, Vellano, CP, Ju, Z, Gagea, M, Liu, S, Mitra, S, Dennison, JB, Lorenzi, PL, Cardnell, R, Diao, L, Wang, J, Lu, Y, Byers, LA, Perou, CM, Lin, SY & Mills, G 2017, 'A murine preclinical syngeneic transplantation model for breast cancer precision medicine', Science advances, vol. 3, no. 4, e1600957. https://doi.org/10.1126/sciadv.1600957
Federico, Lorenzo ; Chong, Zechen ; Zhang, Dong ; McGrail, Daniel J. ; Zhao, Wei ; Jeong, Kang Jin ; Vellano, Christopher P. ; Ju, Zhenlin ; Gagea, Mihai ; Liu, Shuying ; Mitra, Shreya ; Dennison, Jennifer B. ; Lorenzi, Philip L. ; Cardnell, Robert ; Diao, Lixia ; Wang, Jing ; Lu, Yiling ; Byers, Lauren A. ; Perou, Charles M. ; Lin, Shiaw Yih ; Mills, Gordon. / A murine preclinical syngeneic transplantation model for breast cancer precision medicine. In: Science advances. 2017 ; Vol. 3, No. 4.
@article{f826ecdd73b141f2bd1ed1724b916378,
title = "A murine preclinical syngeneic transplantation model for breast cancer precision medicine",
abstract = "We previously demonstrated that altered activity of lysophosphatidic acid in murine mammary glands promotes tumorigenesis. We have now established and characterized a heterogeneous collection of mouse-derived syngeneic transplants (MDSTs) as preclinical platforms for the assessment of personalized pharmacological therapies. Detailed molecular and phenotypic analyses revealed that MDSTs are the most heterogeneous group of genetically engineered mouse models (GEMMs) of breast cancer yet observed. Response of MDSTs to trametinib, a mitogen-activated protein kinase (MAPK) kinase inhibitor, correlated with RAS/MAPK signaling activity, as expected from studies in xenografts and clinical trials providing validation of the utility of the model. Sensitivity of MDSTs to talazoparib, a poly(adenosine 5′-diphosphate–ribose) polymerase (PARP) inhibitor, was predicted by PARP1 protein levels and by a new PARP sensitivity predictor (PSP) score developed from integrated analysis of drug sensitivity data of human cell lines. PSP score–based classification of The Cancer Genome Atlas breast cancer suggested that a subset of patients with limited therapeutic options would be expected to benefit from PARP-targeted drugs. These results indicate that MDSTs are useful models for studies of targeted therapies, and propose novel potential biomarkers for identification of breast cancer patients likely to benefit from personalized pharmacological treatments.",
author = "Lorenzo Federico and Zechen Chong and Dong Zhang and McGrail, {Daniel J.} and Wei Zhao and Jeong, {Kang Jin} and Vellano, {Christopher P.} and Zhenlin Ju and Mihai Gagea and Shuying Liu and Shreya Mitra and Dennison, {Jennifer B.} and Lorenzi, {Philip L.} and Robert Cardnell and Lixia Diao and Jing Wang and Yiling Lu and Byers, {Lauren A.} and Perou, {Charles M.} and Lin, {Shiaw Yih} and Gordon Mills",
year = "2017",
month = "4",
day = "1",
doi = "10.1126/sciadv.1600957",
language = "English (US)",
volume = "3",
journal = "Science advances",
issn = "2375-2548",
publisher = "American Association for the Advancement of Science",
number = "4",

}

TY - JOUR

T1 - A murine preclinical syngeneic transplantation model for breast cancer precision medicine

AU - Federico, Lorenzo

AU - Chong, Zechen

AU - Zhang, Dong

AU - McGrail, Daniel J.

AU - Zhao, Wei

AU - Jeong, Kang Jin

AU - Vellano, Christopher P.

AU - Ju, Zhenlin

AU - Gagea, Mihai

AU - Liu, Shuying

AU - Mitra, Shreya

AU - Dennison, Jennifer B.

AU - Lorenzi, Philip L.

AU - Cardnell, Robert

AU - Diao, Lixia

AU - Wang, Jing

AU - Lu, Yiling

AU - Byers, Lauren A.

AU - Perou, Charles M.

AU - Lin, Shiaw Yih

AU - Mills, Gordon

PY - 2017/4/1

Y1 - 2017/4/1

N2 - We previously demonstrated that altered activity of lysophosphatidic acid in murine mammary glands promotes tumorigenesis. We have now established and characterized a heterogeneous collection of mouse-derived syngeneic transplants (MDSTs) as preclinical platforms for the assessment of personalized pharmacological therapies. Detailed molecular and phenotypic analyses revealed that MDSTs are the most heterogeneous group of genetically engineered mouse models (GEMMs) of breast cancer yet observed. Response of MDSTs to trametinib, a mitogen-activated protein kinase (MAPK) kinase inhibitor, correlated with RAS/MAPK signaling activity, as expected from studies in xenografts and clinical trials providing validation of the utility of the model. Sensitivity of MDSTs to talazoparib, a poly(adenosine 5′-diphosphate–ribose) polymerase (PARP) inhibitor, was predicted by PARP1 protein levels and by a new PARP sensitivity predictor (PSP) score developed from integrated analysis of drug sensitivity data of human cell lines. PSP score–based classification of The Cancer Genome Atlas breast cancer suggested that a subset of patients with limited therapeutic options would be expected to benefit from PARP-targeted drugs. These results indicate that MDSTs are useful models for studies of targeted therapies, and propose novel potential biomarkers for identification of breast cancer patients likely to benefit from personalized pharmacological treatments.

AB - We previously demonstrated that altered activity of lysophosphatidic acid in murine mammary glands promotes tumorigenesis. We have now established and characterized a heterogeneous collection of mouse-derived syngeneic transplants (MDSTs) as preclinical platforms for the assessment of personalized pharmacological therapies. Detailed molecular and phenotypic analyses revealed that MDSTs are the most heterogeneous group of genetically engineered mouse models (GEMMs) of breast cancer yet observed. Response of MDSTs to trametinib, a mitogen-activated protein kinase (MAPK) kinase inhibitor, correlated with RAS/MAPK signaling activity, as expected from studies in xenografts and clinical trials providing validation of the utility of the model. Sensitivity of MDSTs to talazoparib, a poly(adenosine 5′-diphosphate–ribose) polymerase (PARP) inhibitor, was predicted by PARP1 protein levels and by a new PARP sensitivity predictor (PSP) score developed from integrated analysis of drug sensitivity data of human cell lines. PSP score–based classification of The Cancer Genome Atlas breast cancer suggested that a subset of patients with limited therapeutic options would be expected to benefit from PARP-targeted drugs. These results indicate that MDSTs are useful models for studies of targeted therapies, and propose novel potential biomarkers for identification of breast cancer patients likely to benefit from personalized pharmacological treatments.

UR - http://www.scopus.com/inward/record.url?scp=85042035716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042035716&partnerID=8YFLogxK

U2 - 10.1126/sciadv.1600957

DO - 10.1126/sciadv.1600957

M3 - Article

C2 - 28439535

AN - SCOPUS:85042035716

VL - 3

JO - Science advances

JF - Science advances

SN - 2375-2548

IS - 4

M1 - e1600957

ER -